A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

Xiao-Jun Ma, Zuncai Wang, Paula D. Ryan, +27

Cancer Cell

Breast OncologyBreast Cancer PatientsMedicineTwo-gene Expression RatioPathology +7

A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer.

SJ Isakoff, Beth Overmoyer, Nadine Tung, +6

Journal of Clinical Oncology

Surgical OncologyBreast OncologyPathologyPharmacotherapyTumor Biology +14

Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort

Ben S. Wittner, Dennis C. Sgroi, Paula D. Ryan, +9

Clinical Cancer Research

Augmentation of venlafaxine and selective serotonin reuptake inhibitors with zolpidem improves sleep and quality of life in breast cancer patients with hot flashes

Hadine Joffe, Ann Partridge, Anita Giobbie‐Hurder, +5

Menopause The Journal of The North American Menopause Society

Comparison of tissue genotyping (TG) vs circulating tumor DNA (ctDNA) for selection of matched therapy and impact on clinical outcomes among patients with metastatic breast cancer (MBC).

Neelima Vidula, Dejan Juric, Andrzej Niemierko, +11

Journal of Clinical Oncology

Breast OncologyCancer PathologyCancer ManagementPathologyTumor Biology +19

Disparities in Cancer Genetic Risk Assessment and Testing

Meghan Underhill‐Blazey, Tarsha Jones, Karleen Habin

Oncology nursing forum

EpidemiologyGenetic TestingCancer RiskCancer ScreeningGenetics +13

Applying a conceptual model for examining health‐related quality of life in long‐term breast cancer survivors: CALGB study 79804

Electra D. Paskett, James E. Herndon, Jeannette M. Day, +12

Psycho-Oncology

"I Feel Like I Am 100 Years Old!" Managing Arthralgias From Aromatase Inhibitors

Loren Winters, Karleen Habin, Jane Flanagan, +1

Clinical journal of oncology nursing

NursingBreast OncologyLongevityMedicineGynecology +10

Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations

Jing Xu, Tanya E. Keenan, Beth Overmoyer, +10

Breast Cancer Research and Treatment

Breast OncologyPhase Ii TrialMedicineBrca1/2 MutationsPharmacology +6

P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer.

SJ Isakoff, Beth Overmoyer, NM Tung, +9

Cancer Research

Metastatic Breast CancerParp Inhibitor VeliparibBreast OncologyMedicinePharmacology +10